Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Guanylin (GUCA2A) is a 15-amino acid intestinal peptide hormone secreted predominantly by goblet cells of the colon and other epithelial cells throughout the gastrointestinal tract. It acts as the endogenous ligand for guanylate cyclase C (GUCY2C), regulating fluid and electrolyte transport by increasing intracellular cyclic GMP upon receptor activation. Guanylin’s physiological roles include intestinal and renal ion homeostasis, mucosal barrier maintenance, and control of epithelial proliferation. Pathologically, loss of guanylin expression is a frequent, early event in colorectal cancer, linking its activity to tumor suppression and highlighting its value as a biomarker. Therapeutic targeting of the GC-C signaling axis via guanylin-mimetic drugs is clinically validated for bowel disorders such as constipation.
Drugs such as linaclotide, plecanatide, and dolcanatide mimic guanylin by agonizing GC-C, triggering production of cGMP, stimulating chloride and bicarbonate secretion, and reducing fluid absorption for treatment of constipation and irritable bowel syndrome
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Guanylin (GUCA2A).